search
Back to results

Effect of Intrauterine Injection of Hcg Before ET on Clinical Outcomes in IVF/ICSI Cycles

Primary Purpose

Infertility, ART

Status
Completed
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Human Chorionic Gonadotropin
Sponsored by
Assiut University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Infertility focused on measuring hCG, Intrauterine hCG, IVF, ICSI

Eligibility Criteria

18 Years - 43 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • infertility, male or female factor
  • Women undergoing ICSI/IVF

Exclusion Criteria:

  • functional azoospermia
  • submucous uterine myomas or previous myomectomy
  • endometriosis
  • hydrosalpinges without prior excision or occlusion of the tubal ostia

Sites / Locations

  • Assiut University - Women's Health Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention Group

Control Group

Arm Description

Group that will receive intrauterine injection of human Chorionic Gonadotropin before ET

Control Group

Outcomes

Primary Outcome Measures

Live Birth Rate (LBR)
calculated by the number of live births to the number of transferred embryos

Secondary Outcome Measures

Clinical Pregnancy Rate (cPR)
calculated by the percentage of detected clinical pregnancies using ultrasound to the IVF/ICSI cycles in each group
Implantation Rate (IR)
calculated by the number of visualized embryos by transvaginal ultrasound to the number of transferred embryos
Miscarriage rate (MR)
calculated by the ratio of miscarriages to the number of confirmed pregnancies.

Full Information

First Posted
August 1, 2017
Last Updated
September 26, 2022
Sponsor
Assiut University
search

1. Study Identification

Unique Protocol Identification Number
NCT03238807
Brief Title
Effect of Intrauterine Injection of Hcg Before ET on Clinical Outcomes in IVF/ICSI Cycles
Official Title
Effect of Intrauterine Injection of Human Chorionic Gonadotropin Before Embryo Transfer on Clinical Outcomes in In-vitro Fertilization/Intracytoplasmic Sperm Injection Cycles: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2022
Overall Recruitment Status
Completed
Study Start Date
July 8, 2018 (Actual)
Primary Completion Date
October 4, 2020 (Actual)
Study Completion Date
October 4, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Assiut University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Subfertility is the inability to conceive after 12 months of regular unprotected sexual intercourse. Around 15% of couples suffer from subfertility. As a treatment for subfertility, Assisted Reproductive Techniques (ART) have been a choice for subfertile couples. In Egypt in 2010, Pregnancy Rate was calculated to be 36.2%, Live Birth Rate to be 25.7%. Implantation is the process by which the embryo adheres to the wall of the uterus. Endometrial receptivity plays the most important role for successful implantation after embryo quality. It is estimated that up to 70% of early pregnancy losses are due to failure of implantation. Despite extensive research, the embryo-maternal dialogue that orchestrates the implantation process is still not fully understood. Much effort has been done in the last decades to detect factors affecting Implantation and improve endometrial receptivity. Human Chorionic Gonadotropin (hCG) is a placental glycoprotein hormone that required to maintain pregnancy. Recent research data demonstrates that hCG is secreted very early by the embryo before implantation to facilitate it. hCG has been proved to cause attraction of inflammatory cells, promote angiogenesis, regulate chemical mediators at the endometrium. These effects proceed the classical role of hCG during pregnancy and could be a directly involved in and facilitating the implantation process. Studies have been conducted to study the effect of injection of different concentrations of hCG inside the uterine cavity before Embryo Transfer (ET) to improve endometrial receptivity and outcomes of In-Vitro Fertilization (IVF) or Intra-Cytoplasmic Sperm Injection (ICSI) cycles. A recent systematic review was conducted on 12 studies performing intrauterine injection of different doses of hCG before ET. Results of this study showed that there is increased pregnancy outcome after injection of intrauterine 500 IU of hCG. The study recommended a definitive large clinical trial with live birth as the primary outcome. There was no evidence that miscarriage was influenced by intrauterine hCG administration, irrespective of embryo stage at transfer or dose of intrauterine hCG. Aim of the study: To detect whether intrauterine injection of hCG before ET improves clinical outcomes in IVF/ICSI cycles.
Detailed Description
This study is a Randomized Controlled Trial (RCT) to be done at ART center of Women's Health Hospital, Assiut university, Egypt. All steps for IVF/ICSI procedure, from the beginning of the induction for controlled ovarian stimulation until just before the procedure of ET, will be done for all enrolled patients as routinely decided according to the local protocol of the ART center in Women Health Hospital, Assiut University. In the day of ET, number and quality of Embryos will be decided according to the routine practice guided by the local protocol. The intervention preparation will be prepared by adding one vial of hCG containing 5000 IU to 1mL of tissue culture medium (Continuous Single Culture, IrvineScientific). To obtain 500 IU of hCG, 0.1 milliLiter (mL) of the preparation will be injected inside the uterus before ET in the study group. For the control group, 0.1 mL of the tissue culture medium without hCG will be injected inside the uterus before the ET. For both groups we will use Intra-Uterine Insemination (IUI) catheter (Sperm Trans, Sperm Processor) to inject the solution inside the uterine cavity 4 minutes before ET. We will standardize the procedure of ET for all women apart from the intervention versus control step. All women participating in the study will be put in lithotomy position. Cusco's speculum will be introduced to visualize the cervix. Guided by transabdominal ultrasound with a full bladder, the ET catheter (Cook Sydney IVF Catheter) will be introduced through the cervical os into the uterine cavity. After introduction of the catheter into the uterine cavity loaded embryos will be injected inside the cavity 0.5 cm from the fundus. Biochemical pregnancy test will be done 14 days after ET by measuring hCG in the woman's serum. If the test result is positive (according to the standard values that is used in the laboratory), a transvaginal ultrasound will be done 3 weeks following the positive biochemical test, to document the visualization of gestational sac, fetal pole and cardiac pulsation. Pregnancy rate (PR) is calculated by the number of women with positive biochemical pregnancy test to the number of women enrolled in each group. The clinical pregnancy was defined as a viable pregnancy when there is evidence of a gestational sac, embryo and fetal heart rate at the time of ultrasound evaluation. Clinical Pregnancy Rate (cPR) is calculated by the percentage of detected clinical pregnancies using ultrasound to the IVF/ICSI cycles in each group. Implantation rate (IR) is calculated by the number of visualized embryos by transvaginal ultrasound to the number of transferred embryos. While Live Birth Rate (LBR) is calculated by the number of live births to the number of transferred embryos. Miscarriage rate (MR) is calculated by the ratio of miscarriages to the number of confirmed pregnancies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility, ART
Keywords
hCG, Intrauterine hCG, IVF, ICSI

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized Controlled Trial
Masking
ParticipantCare Provider
Masking Description
Double-Blinded
Allocation
Randomized
Enrollment
181 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention Group
Arm Type
Experimental
Arm Description
Group that will receive intrauterine injection of human Chorionic Gonadotropin before ET
Arm Title
Control Group
Arm Type
No Intervention
Arm Description
Control Group
Intervention Type
Drug
Intervention Name(s)
Human Chorionic Gonadotropin
Other Intervention Name(s)
Epifasi
Intervention Description
500 IU of human Chorionic Gonadotropin
Primary Outcome Measure Information:
Title
Live Birth Rate (LBR)
Description
calculated by the number of live births to the number of transferred embryos
Time Frame
9 months
Secondary Outcome Measure Information:
Title
Clinical Pregnancy Rate (cPR)
Description
calculated by the percentage of detected clinical pregnancies using ultrasound to the IVF/ICSI cycles in each group
Time Frame
5 weeks
Title
Implantation Rate (IR)
Description
calculated by the number of visualized embryos by transvaginal ultrasound to the number of transferred embryos
Time Frame
5 weeks
Title
Miscarriage rate (MR)
Description
calculated by the ratio of miscarriages to the number of confirmed pregnancies.
Time Frame
3 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
43 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: infertility, male or female factor Women undergoing ICSI/IVF Exclusion Criteria: functional azoospermia submucous uterine myomas or previous myomectomy endometriosis hydrosalpinges without prior excision or occlusion of the tubal ostia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ahmed Makhlouf, MD
Organizational Affiliation
Assiut University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Hazem Saadeldine, MD
Organizational Affiliation
Assiut University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Esraa Badran, MD
Organizational Affiliation
Assiut University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Karim Abdallah, M.Sc
Organizational Affiliation
Assiut University
Official's Role
Study Director
Facility Information:
Facility Name
Assiut University - Women's Health Hospital
City
Assiut
ZIP/Postal Code
71515
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
All of the individual participant data collected during the trial, after deidentification to Researchers who provide a methodologically sound proposal To achieve aims in the approved proposal.
IPD Sharing Time Frame
Immediately after publication indefinitely.
IPD Sharing Access Criteria
Proposals should be directed to karimsayed88@hotmail.com. To gain access, data requestors will need to sign a data access agreement.
Citations:
PubMed Identifier
34412973
Citation
Abdallah KS, Makhlouf A, Badran E, El-Nashar IM, Al-Hussaini TK, Farghaly T, Mohamed HS, Mol BW, Abdelmagied AM. Intrauterine injection of HCG before embryo transfer: a parallel, double-blind randomized trial. Reprod Biomed Online. 2021 Oct;43(4):663-669. doi: 10.1016/j.rbmo.2021.06.011. Epub 2021 Jun 20.
Results Reference
result

Learn more about this trial

Effect of Intrauterine Injection of Hcg Before ET on Clinical Outcomes in IVF/ICSI Cycles

We'll reach out to this number within 24 hrs